Ryoncil® Net Revenues Increase for the Quarter to US$30M

About this update from Mesoblast Limited

[{"type":"image","alt":"Mesoblast Limited","displaySize":"","headline":null,"caption":"Mesoblast Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qVvwFFYM1KHQf5WBcCEDQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df","width":289,"height":38}},"lazy":false},{"type":"text","content":"Activity Report for Quarter Ended December 31, 2025 (Appendix 4C)","length":65,"tagName":"p"},{"type":"text","content":"NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second fiscal quarter ended December 31, 2025.","length":265,"tagName":"p"},{"type":"text","content":"“This quarter was highlighted by continued strong Ryoncil® sales and the establishment of a new lower-cost non-dilutive financing facility both of which enable greater flexibility for strategic partnerships and pursuit of label expansion for Ryoncil®,” said Mesoblast Chief Executive Dr. Silviu Itescu.","length":302,"tagName":"p"},{"type":"text","content":"FINANCIAL HIGHLIGHTS FOR QUARTER ENDED DECEMBER 31, 20251","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ryoncil® gross sales for the quarter were US$35 million, a 60% increase on the prior quarter ended September 30, 2025, and net revenues were US$30 million.1","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Mesoblast entered into a new non-dilutive credit-line totaling US$125 million at a fixed interest rate of 8.00% per annum, a substantial reduction from Mesoblast's current debt facilities, with a five-year interest only period. The initial US$75 million drawn is unsecured until the remainder of the secured debt is repaid, no later than July 8, 2026, after which the entire new facility will be secured solely with the Temcell2 royalty.","length":441,"tagName":"p"}]},{"val":[{"type":"text","content":"Mesoblast had US$130 million of cash at December 31, 2025. Net operating cash spend for the quarter was US$16 million. Mesoblast expects to see reduction in net cash spend ov...

More updates from Mesoblast Limited